Immunotherapy combo shows promise in Hard-to-Treat colorectal cancer

NCT ID NCT03388190

Completed Disease control Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with a specific type of metastatic colorectal cancer (MSS/pMMR). Eighty participants received either the combination or chemotherapy alone. The main goal was to see if the combo slowed cancer growth. The study also tracked side effects to assess safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to: If successful, this combination could offer a new treatment option that delays cancer progression for people with a common type of metastatic colorectal cancer.
What could go wrong: This is a phase 2 trial with only 80 participants, so results are preliminary. The added immunotherapy may not improve outcomes and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Akershus University Hospital

Oslo, 1478, Norway
Haukeland University Hospital

Bergen, 5021, Norway
Hospital of Southern Norway, Department of Oncology

Kristiansand, 4604, Norway
Oslo University Hospital

Oslo, 0424, Norway
St Olav's Hospital - Trondheim University Hospital

Trondheim, 7006, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.